본문 바로가기
KERD
논문KCI 등재

Anthracycline 기반 항암화학요법 후 유방암의 단백질발현 변화

Changes in Protein Expression in Breast Cancer afterAnthracycline-Based Chemotherapy

박인애|이재옥|이호창
대한병리학회|2007.06|Journal of Pathology and Translational Medicine|제41권 제3호|pp. 165-170

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류병리학

초록

Abstract

Background : Anthracyclines are the standard agents used to treat patients with advanced breast carcinoma. Some molecules are reportedly associated with anthracycline resistance; however, there has been some controversy surrounding these claims. The gain or loss of certain molecules after chemotherapy can explain the discrepancies in the results. Methods : We evaluated the expression levels of the estrogen receptor (ER), p53, and bcl-2 in specimens obtained from twenty patients with advanced breast cancer before and after anthracyclinebased chemotherapy using immunohistochemistry (IHC). We also examined HER2/neu expression in these specimens using IHC and fluorescence in situ hybridization (FISH) analysis. Results : After chemotherapy, one of the twenty cases (5%) showed decreased ER expression, one (5%) showed decreased p53 expression, and one (5%) showed increased bcl-2 expression. IHC and FISH analysis in pre- and post-chemotherapy specimens showed that the expression of HER2/neu changed from equivocal to negative in one case (5%). Conclusion : Our results showed that the expression levels of HER2/neu, ER, p53 and bcl-2 remained stable after chemotherapy, although the statistical significance of these results may not be validated due to the small number of cases. We also suggested that the resistance to anthracycline- based chemotherapy might not be associated with the modification of these molecules.

참고문헌 (28)

  1. "et al. Tyrosine kinase receptorwith extensive homology to EGF receptor shares chromosomal locationwith neu oncogene. Science 1985", pp.1132~9
  2. "ERBB2 oncogene in human breast cancer and its clinical significance", 34, pp.791~808 (1998)
  3. "Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer", 79, pp.1220~1226 (1999)
  4. "neu", erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer, 1998, pp.16, 1340~1349
  5. "Prognostic value of c-erbB2 expression in breast cancer", 79, pp.216~223 (2002)
  6. "2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology", 16, pp.1865~1878 (2001)
  7. "Rosen’s breast pathology. 2nd ed", pp.325~364 (2001), Philadelphia: Lippincott Williams and Wilkins
  8. "The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer", 120, pp.1311~1317 (2007)
  9. "Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003", 35, pp.781~784 (2003), Philadelphia, PA. Hum Pathol
  10. "Predictive value of topoisomerase II and other prognostic factors for epirubicin chemotherapy in advanced breast cancer", 77, pp.2267~2273 (1998)
  11. "p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer", 16, pp.470~479 (1998)
  12. "No significant predictive value of c-erbB-2 or p53 expression regarding sensitively to primary chemotherapy or radiotherapy in breast cancer", 76, pp.27~33 (1998)
  13. "Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy", 40, pp.205~211 (2004)
  14. "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing, 2007, pp.25, 118~145
  15. "et al. The effects of chemotherapyon morphology apoptosis and oncoproteinexpression in primary breast carcinoma. Br J Cancer 1994", pp.335~41
  16. "Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy", 78, pp.97~103 (2003)
  17. "Changes in biological markers after primary chemotherapy for breast cancers", 61, pp.301~305 (1995)
  18. "Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy", 10, pp.91~98 (2003)
  19. "HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process", 94, pp.2169~2173 (2002)
  20. "HER-2", neu assessment in primary chemotherapy treated breast carcinoma: no evidence of gene profile changing, 2003, pp.80, 207~214
  21. "Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of HER2", neu in patients with breast cancer, 2003, pp.82, 207~213
  22. "Stability of the HER2 gene after primary chemotherapy in advanced breast cancer", 446, pp.136~141 (2005)
  23. "HER2", neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer, 2005, pp.446, 489~496
  24. "Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP", 20, pp.4373~4378 (2000)
  25. "Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer", 67, pp.818~826 (2007)
  26. "Changes of topoisomerase II expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival", 12, pp.1501~1506 (2006)
  27. "Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer", 12, pp.7054~7058 (2006)
  28. "Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer", 13, pp.1198~1207 (2007)

관련 논문AI추천

유방 병변의 악성 진행에 따른 Survivin 단백 발현강석진, 강창석, 유진영, 이교영, 이은정, 정지한, 정찬권, 최현주대한병리학회 · Journal of Pathology and Translational Medicine2007 · 제41권 제4호유방의 침윤성 관암종에서 p21, p53 및 bcl-2 단백의 발현문형배, 윤기중, 조향정대한병리학회 · Journal of Pathology and Translational Medicine2003 · 제37권 제6호Chemoradiotherapy Alters Protein Expression in Glioblastoma Multiforme고용, 고성호, 김재민, 류제일, 박현희, 이규용, 이영주, 정진환, 최호진, 한명훈, 황미나대한신경과학회 · Journal of Clinical Neurology2020 · 제16권 제4호유방암종에서 p27kip1 단백의 세포 내 발현 위치와 예후와의 관련성김대철, 조세헌, 홍숙희, 홍영습대한병리학회 · Journal of Pathology and Translational Medicine2006 · 제40권 제3호유방암종의 MMP-2와 MMP-9 발현과 예후 인자와의 연관성박설미, 윤혜경대한병리학회 · Journal of Pathology and Translational Medicine2004 · 제38권 제2호The Differential Gene Expression Profiles between Sensitive and Resistant Breast Cancer Cells to Adriamycin by cDNA Microarray배준민, 안명주, 안준익, 유동현, 이기환, 이용성, 이혜숙, 장정순, 최정혜대한암학회 · Cancer Research and Treatment2004 · 제36권 제1호

이 간행물의 다른 논문 (13건)

위암에서 예후인자로서 점액소 표현형과 CDX2 단백 발현의 역할이교영, 정찬권, 송교영, 최명규, 박조현, 홍영선, 박경신pp. 139-148위장관계 신경내분비성 종양의 임상 및 병리학적 특성;65 증례 분석김애리, 안정석, 최정우, 김인선, 이현주, 김한겸, 신봉경, 김현철pp. 149-157유방암의 Claudin-7 발현 감소와 침습력 및 핵등급과의관련성배영경, 석상희, 이수정, 황태윤, 강수환pp. 158-164췌장관 샘암종에서 c-erbB-2와 Cyclooxygenase-2의 면역조직화학적 발현윤성수, 최준혁, 최혜정, 김홍진pp. 171-175위샘암 환자의 예후 인자로서 Thymosin-β4의 용성한지영, 김예지, 최석진, 박인서, 김준미, 주영채, 김루시아pp. 176-182
원문 보기